BBNX · Beta Bionics, Inc. · Documents
$17.75
-3.64 (-17.02%)
At close · Oct 28
Return incl. dividend (before tax)
Q1 2026 earnings call transcript
Market Cap
$962.33M
Shares
54.37M
Volume · Oct 28
2.46M
Avg daily vol (3M)
1.31M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Beta Bionics reported third-quarter net sales of $35.5 million, up 30%, and a net loss of $24.4 million. Full-year 2026 revenue guidance increased to approximately $124 million to $126 million, while gross margin guidance remained 58.5% to 59.5%. | 2026-10-27 | — | |
| 10-Q | Beta Bionics reported nine-month net sales of $95.1 million, up from $68.1 million, and a net loss of (69,651), compared with (59,734), in thousands. | 2026-10-27 | 2026-09-30 | |
| 8-K | — | 2026-09-17 | 2026-09-15 | |
| 8-K | — | 2026-09-15 | 2026-09-14 | |
| 8-K | — | 2026-07-29 | — | |
| 10-Q | — | 2026-07-29 | 2026-06-30 | |
| 8-K | — | 2026-05-22 | 2026-05-21 | |
| 8-K | — | 2026-05-21 | — | |
| 10-Q | — | 2026-04-21 | 2026-03-31 | |
| 8-K | — | 2026-04-21 | — | |
| DEFA14A | — | 2026-04-10 | — | |
| ARS | — | 2026-04-10 | 2025-12-31 | |
| DEF 14A | — | 2026-04-10 | 2026-05-21 | |
| S-3ASR | — | 2026-02-24 | — | |
| 10-K | — | 2026-02-24 | 2025-12-31 | |
| 8-K | — | 2026-02-17 | — | |
| 8-K | — | 2026-01-30 | 2026-01-29 | |
| 8-K | — | 2026-01-08 | — | |
| 8-K | — | 2025-10-28 | — | |
| 10-Q | — | 2025-10-28 | 2025-09-30 | |
| 8-K | — | 2025-07-29 | — | |
| 10-Q | — | 2025-07-29 | 2025-06-30 | |
| 8-K | — | 2025-06-23 | 2025-06-22 | |
| 10-Q | — | 2025-05-06 | 2025-03-31 | |
| 8-K | — | 2025-05-06 | — | |
| 10-K/A | — | 2025-03-28 | 2024-12-31 | |
| 8-K | — | 2025-03-27 | 2025-03-26 | |
| 10-K | — | 2025-03-25 | 2024-12-31 | |
| 8-K | — | 2025-03-25 | — | |
| 8-K | — | 2025-01-31 | — | |
| S-1/A | — | 2025-01-28 | — | |
| S-1/A | — | 2025-01-23 | — | |
| S-1/A | — | 2025-01-22 | — | |
| S-1 | — | 2025-01-06 | — |
Showing 1–34 of 34 filings
Key facts
CIK
1674632
CUSIP
08659B102
13F (30d)
22 filings
22 filers
Visit website
Investor relations